GSK - GlaxoSmithKline plc

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• AbbVie, GSK, Teva cited as FTC tackles improper Orange Book patents
• Elliott could push for sale, cost cutting at BioMarin - analyst
• Strong sales of new RSV vaccine drives upgrade to GSK's outlook
• GSK reports Q3 results, raises FY23 guidance
• GSK seen reporting higher Q3 earnings in wake of forecast raise
• GSK inks $1B deal to obtain rights to hepatitis B drug from J&J
• GSK is said to have taken early lead over Pfizer in RSV vaccine rollout
• GSK inks new data licensing pact with 23andMe
• GSK Phase 3 trial for Jemperli succeeds in endometrial cancer
• Pharma, PBMs spar over rising drug costs amid public scrutiny
• Concurrent use of COVID and flu shots is linked to stroke risk in older adults
• GSK's respiratory virus vaccine delivers positive trial results
• Drug retailers, makers face mounting litigation over decongestant products
• Eli Lilly, Novo among notable decliners in pharma weakness
• GSK settles more Zantac lawsuits in California
• GSK signs £2.5B deal to market shingles vaccine, Shingrix in China
• Ideaya Bio picks cancer candidate for GSK collaboration
• FDA experts recommend changes to flu vaccines
• GSK to trim Haleon stake in over $1B share sale
• Moderna eyes late-stage trial for COVID/flu combo shot